Pfizer: drug improves overall survival in myeloma

(CercleFinance.com) - Pfizer announced on Friday that a phase 2 clinical trial showed its Elrexfio immunotherapy extended the life expectancy of patients with relapsed or refractory multiple myeloma by more than two years.


According to the company, the 123 participants in the trial enjoyed a median overall survival of 24.6 months, while progression-free survival reached 17.2 months.

Last year, the FDA granted Elrexfio marketing authorisation for the treatment of relapsed or refractory multiple myeloma (RRMM) in adults who had received at least three prior lines of treatment.

The European Commission followed suit, granting conditional authorisation for the product in the same indication.

Multiple myeloma, commonly known as myeloma, is an aggressive, currently incurable type of blood cancer that affects plasma cells produced by the bone marrow.


Translated with DeepL.com (free version)

Copyright (c) 2024 CercleFinance.com. All rights reserved.